Cresilon snagged its second FDA clearance for human use. The FDA granted 510(k) clearance to Traumagel, the startup’s gel that can stop bleeding in just seconds, for temporary external use to control moderate to severe bleeding.
Cresilon, a startup that makes a hemostatic gel to stop bleeding, has raised $25 million in a Series A-4 financing round. The round brings the company's total funding to date to nearly $82 million. The funds will help support Cresilon's entrance into the human health market, as its gel is currently used only by veterinarians.
PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies.
Scientific innovation has the potential to provide two key components for advancing anti-aging research.
In the not-too-distant future, we may see the standards of care for many illnesses transformed from reactionary loss prevention — stopping the loss of the body’s function — to the regeneration of full functionality and health.